Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-018-0422-z
Abstract: Allogeneic hematopoietic cell transplant (alloHCT) represents a significant therapeutic approach for patients diagnosed with lymphoid malignancies (LM). However, relapse remains a major cause of treatment failure. In this scenario, a number of strategies have been… read more here.
Keywords: dli; allohct; allogeneic hematopoietic; donor ... See more keywords
Easix As Prediction Score before CAR-T Cells Vs Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Relapsed/Refractory (r/r) Large B Cell Lymphoma (LBCL)
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-139615
Abstract: BACKGROUND: In a previous study we have shown that CD19-directed chimeric antigen receptor (CAR)-T cells do not appear to be inferior to alloHCT when used as standard cellular immunotherapy (CI) for patients with multiply r/r… read more here.
Keywords: allohct; research funding; car; easix ... See more keywords